Related Experiment Video
Updated: Aug 15, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity
Maria D F S Barbosa1, Jost Vielmetter, Seung Chu
1Xencor, Inc., 111 W. Lemon Avenue, Monrovia, CA 91016, USA. mbarbosa@xencor.com
A specific gene variant (DRB1*0701) is linked to antibody development against interferon-beta (IFN-beta) in multiple sclerosis (MS) patients. HLA typing could identify those at risk, guiding alternative treatment choices.
Area of Science:
- Immunology
- Genetics
- Neurology
Background:
- Interferon-beta (IFN-beta) is a primary treatment for multiple sclerosis (MS).
- A notable proportion of MS patients develop anti-IFN-beta antibodies, compromising treatment effectiveness.
- Understanding the genetic basis of this immunogenicity is crucial for optimizing MS therapy.
Purpose of the Study:
- To investigate the association between MHC class II alleles and anti-IFN-beta antibody response in MS patients.
- To identify specific IFN-beta epitopes recognized by B cells and T cells in relation to the DRB1*0701 allele.
- To explore the potential of HLA typing for predicting anti-IFN-beta antibody formation.
Main Methods:
- Peptide-binding assays were employed using B cell lines expressing the DRB1*0701 allele.
- Epitope mapping of IFN-beta was performed to identify immunogenic regions.
- Peripheral blood mononuclear cells (PBMCs) from IFN-beta treated patients were analyzed for T-cell activation.
Main Results:
- A significant association was found between the MHC class II allele DRB1*0701 and the development of anti-IFN-beta antibodies.
- Specific IFN-beta epitopes were identified that trigger B cell binding and T cell activation in patients with the DRB1*0701 allele.
- T-cell activation responses in PBMCs confirmed the role of cellular immunity in IFN-beta immunogenicity.
Conclusions:
- HLA typing, specifically for the DRB1*0701 allele, may serve as a predictive tool for identifying MS patients at risk of developing anti-IFN-beta antibodies.
- This genetic screening can inform decisions regarding alternative therapies for MS.
- Further research into the factors driving anti-IFN-beta antibody responses will aid in developing less immunogenic IFN-beta therapeutics.
Related Concept Videos
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Inhibitors of Viral Protein Synthesis
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Antigen Processing Pathways
MHC Class I: Presenting Endogenous...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Type I Diabetes II: Pathophysiology
